Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A, Schlosser A, Keupp A, Trautwein N, Johann P, Wölfl M, Lager J, Monoranu CM, Walz JS, Henkel LM, Krauß J, Ebinger M, Schuhmann M, Thomale UW, Pietsch T, Klinker E, Schlegel PG, Oyen F, Reisner Y, Rammensee HG, Eyrich M. Marcu A, et al. Among authors: walz js. J Immunother Cancer. 2021 Oct;9(10):e003404. doi: 10.1136/jitc-2021-003404. J Immunother Cancer. 2021. PMID: 34599019 Free PMC article.
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS. Backert L, et al. Among authors: walz s, walz js. Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918. Oncotarget. 2017. PMID: 28159928 Free PMC article.
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
Nelde A, Walz JS, Kowalewski DJ, Schuster H, Wolz OO, Peper JK, Cardona Gloria Y, Langerak AW, Muggen AF, Claus R, Bonzheim I, Fend F, Salih HR, Kanz L, Rammensee HG, Stevanović S, Weber AN. Nelde A, et al. Among authors: walz js. Oncoimmunology. 2016 Dec 23;6(3):e1219825. doi: 10.1080/2162402X.2016.1219825. eCollection 2017. Oncoimmunology. 2016. PMID: 28405493 Free PMC article.
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells.
Heidenreich F, Rücker-Braun E, Walz JS, Eugster A, Kühn D, Dietz S, Nelde A, Tunger A, Wehner R, Link CS, Middeke JM, Stölzel F, Tonn T, Stevanovic S, Rammensee HG, Bonifacio E, Bachmann M, Zeis M, Ehninger G, Bornhäuser M, Schetelig J, Schmitz M. Heidenreich F, et al. Among authors: walz js. Haematologica. 2017 Nov;102(11):e460-e464. doi: 10.3324/haematol.2017.167312. Epub 2017 Aug 24. Haematologica. 2017. PMID: 28838995 Free PMC article. No abstract available.
The immunopeptidomic landscape of ovarian carcinomas.
Schuster H, Peper JK, Bösmüller HC, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanović S, Staebler A, Wagner P. Schuster H, et al. Among authors: walz js. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1. Proc Natl Acad Sci U S A. 2017. PMID: 29093164 Free PMC article.
The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G. Neidert MC, et al. Among authors: walz js. Acta Neuropathol. 2018 Jun;135(6):923-938. doi: 10.1007/s00401-018-1836-9. Epub 2018 Mar 20. Acta Neuropathol. 2018. PMID: 29557506
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
Nelde A, Kowalewski DJ, Backert L, Schuster H, Werner JO, Klein R, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S, Walz JS. Nelde A, et al. Among authors: walz js. Oncoimmunology. 2018 Feb 14;7(4):e1316438. doi: 10.1080/2162402X.2017.1316438. eCollection 2018. Oncoimmunology. 2018. PMID: 29632711 Free PMC article.
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS. Bilich T, et al. Among authors: walz js. Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10. Blood. 2019. PMID: 30530751 Free article.
MHCquant: Automated and Reproducible Data Analysis for Immunopeptidomics.
Bichmann L, Nelde A, Ghosh M, Heumos L, Mohr C, Peltzer A, Kuchenbecker L, Sachsenberg T, Walz JS, Stevanović S, Rammensee HG, Kohlbacher O. Bichmann L, et al. Among authors: walz js. J Proteome Res. 2019 Nov 1;18(11):3876-3884. doi: 10.1021/acs.jproteome.9b00313. Epub 2019 Oct 22. J Proteome Res. 2019. PMID: 31589052
92 results